|
業務類別
|
Biotechnology |
|
業務概覽
|
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases. |
| 公司地址
| 1715 38th Street, Boulder, CO, USA, 80301 |
| 電話號碼
| +1 720 262-7002 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.edgewisetx.com |
| 員工數量
| 146 |
| Dr. Kevin Koch, PhD |
President, Chief Executive Officer and Director |
美元 670.00K |
23/04/2026 |
| Dr. Alan Russell, PhD |
Chief Scientific Officer and Director |
美元 499.58K |
23/04/2026 |
| Mr. Michael P. Nofi |
Chief Financial Officer and Principal Accounting Officer |
美元 67.81K |
23/04/2026 |
| Mr. John R. Moore |
General Counsel |
-- |
23/04/2026 |
| Dr. Behrad Derakhshan, PhD |
Chief Operating Officer |
美元 520.00K |
23/04/2026 |
| Dr. Joanne M. Donovan, M.D.,PhD |
Chief Medical Officer |
美元 530.36K |
23/04/2026 |
|
|
| Dr. Kevin Koch, PhD |
President, Chief Executive Officer and Director |
23/04/2026 |
| Dr. Jonathan C. Fox, F.A.C.C.,M.D.,PhD |
Independent Director |
23/04/2026 |
| Dr. Alan Russell, PhD |
Chief Scientific Officer and Director |
23/04/2026 |
| Dr. Badreddin Edris, PhD |
Independent Director |
23/04/2026 |
| Dr. Jonathan D. Root, M.D. |
Independent Director |
23/04/2026 |
| Ms. Arlene M. Morris |
Independent Director |
23/04/2026 |
| Mr. Christopher Nathan Martin |
Independent Director |
23/04/2026 |
| Ms. Laura A. Brege |
Independent Director |
23/04/2026 |
| Dr. Peter Thompson, M.D. |
Chairman of the Board |
23/04/2026 |
|
|
|
|
